Volume 7 Issue 9 - 2018
Mesenchymal Stem Cell - A Ray of Hope in the Management of ILD
Anand Agrawal*
Professor and Head, Department of Respiratory Medicine, BPS Government Medical College for Women, Khanpur Kalan, Sonepat, Haryana, India
*Corresponding Author: Anand Agrawal, Professor and Head, Department of Respiratory Medicine, BPS Government Medical College for Women, Khanpur Kalan, Sonepat, Haryana, India.
Received: July 12, 2018; Published: August 02, 2018
Citation: Anand Agrawal. “Mesenchymal Stem Cell - A Ray of Hope in the Management of ILD”. EC Pulmonology and Respiratory Medicine 7.9 (2018): 617-619.
Interstitial fibrosis is a devastating condition with no effective treatment yet now, however development of cell therapies as well as bioengineering approaches for lung ailment has been highlighted over the past decade [1-3]. Although more than hundred different forms of interstitial lung disease (ILD) have been described in literature with numerous gene variants, IPF is the most common form among them, representing 45% of the total with high morbidity and mortality along with approximately 20% survival of 5-year [4,5]. Current evidence suggests that the areas of fibrosis seen in lungs of patients with IPF share many features with normal aging, such as genomic instability, telomere attrition, mitochondrial dysfunction, cellular senescence, and immune dysregulation. Because of the degenerative course of the disease, as well as lack of a definitive therapy for IPF other than lung transplantation, there is a continuous need to find new options for IPF treatment. Some pharmacological therapies e.g. corticosteroids, azathioprine, N-acetylcysteine, Pirfenidone and etanercept have also been under practice, despite of insignificant long term benefit. Therefore, cellular therapies have emerged as a promising option, and the use of MSCs is consistently being studied [6].
In current era, stem cell therapy represents the great covenant for the future of molecular medicine. In fact several diseases can be slowed or even blocked by stem cell transplantation (SCT) according to recent research. Among the various stem cell population, mesenchymal stem cells (MSCs), which were discovered by Friedenstein., et al. in 1968, belongs to a class of multipotent stem cells with self-proliferation and differentiation potential [7]. It found principally in the bone marrow of adults though can be isolated from different tissues e.g. adipose, liver, tendons, synovial membrane, amniotic fluid, placenta, umbilical cord, as well as teeth, and giving rise to skeletal muscle cells, blood, fat, vascular, uro-genital systems, in addition it also generate connective tissues throughout the body [8,9].
Copyright: © 2018 Anand Agrawal. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

News and Events

Submission Timeline for June Issue

E-Cronicon delightfully welcomes the authors for submission of novel research towards July issue of respective journals. Submissions are accepted on/before July 09, 2019.

Certification for each Publication

Corresponding Authors will be issued a "Publication Certificate" with all the Co-Authors included as a token of appreciation for publishing their work with respective journals.

Best Article of the Issue

The Editors of respective journals will elect one Best Article after each issue release and the authors of the selected article will be provided with a certificate of "Best Article of the Issue".

Certifying for Review

E-Cronicon certify the Editors for their first review done towards respective journals.

Latest Articles

Recently published articles will be updated immediately after publication in respective journals.

Share this article

Visitors: 3928535